A 2016 systematic survey of 4,484 HIV-1-infected individuals established that viral load, duration of untreated infection, and viral diversity independently drive the evolution of broadly neutralizing antibodies (bnAbs), that Black participants induce bnAbs at higher rates than white participants for unknown mechanistic reasons, and that the infected viral subtype biases which bnAb class develops (CD4-binding-site bnAbs enriched in subtype B infection, V2-glycan bnAbs in non-subtype B infection). The unresolved problem is to identify the mechanistic determinants behind these observations — the basis of host-population differences in bnAb induction, the native envelope-trimer features that bias bnAb-class specificity by subtype, and how the natural-infection exposure drivers relate to bnAb induction through vaccination rather than chronic infection — which the survey's authors describe as key host, disease and viral determinants that remain to be unraveled and harnessed for bnAb-based vaccine design. A decade of follow-up work has replicated the subtype and exposure associations and achieved rapid V2-apex bnAb induction in macaques, but none of these determinants is settled in humans, and the resolution of plasma epitope-specificity mapping in large cohorts still limits the class-level evidence.

Background

Broadly neutralizing antibodies (bnAbs) are antibodies that neutralize a wide range of genetically diverse HIV-1 strains, rather than only the infecting virus; they are a central goal of HIV-1 vaccine design because they can block infection in animal models and are routinely isolated from a minority of people with HIV. The sole viral antigen on the virion surface is the envelope glycoprotein (Env), a trimer of three gp120/gp41 protomers, and bnAbs target a handful of conserved epitope classes on it: the CD4 binding site (CD4bs, the region gp120 uses to engage the CD4 receptor), the V2-glycan apex (a glycan-dependent site at the trimer's tip formed around the second variable loop), the V3-glycan patch (a glycan-shielded site near the third variable loop), and the membrane-proximal external region (MPER, a segment of gp41 adjacent to the viral membrane). Assigning the specificity of plasma neutralizing activity in large cohorts relies on computational 'neutralization fingerprinting' — deconvolving serum neutralization patterns measured on a panel of diverse viruses against the known neutralization signatures of reference bnAbs. In 2016, Rusert, Kouyos, Trkola and colleagues reported in Nature Medicine a systematic bnAb survey of 4,484 HIV-1-infected participants of the Swiss HIV Cohort Study (SHCS) and the Zurich Primary HIV Infection Study (ZPHI), identifying 239 bnAb inducers (doi:10.1038/nm.4187). In that survey each plasma was screened in a primary eight-virus TZM-bl-based Env pseudovirus neutralization assay at a 1:150 dilution and given a cumulative score summing its neutralization scores against the eight viruses; a 'bnAb inducer' is a participant in the elite (cumulative score 15–24; n = 58, 1.3%) or broad (score 10–14; n = 181, 4.0%) category, which together give the 239 inducers of 4,484 (≈5.3%). In a secondary screen of the top-scoring plasmas against 40 viruses, breadth was defined as the percentage of strains neutralized at titers >1:100 (>50% marking broad neutralization) and potency as the median NT50 across all tested strains (high potency NT50 >1:500). Three exposure-related parameters — viral load, length of untreated infection, and viral sequence diversity — independently drove bnAb evolution. Black participants showed significantly higher bnAb induction rates than white participants (P = 0.0086–0.038), an association that persisted in multivariable models including all measured demographic, viral and disease parameters, with no mechanistic explanation. Neutralization fingerprinting revealed strong subtype dependence of bnAb specificity: CD4bs bnAbs were more frequent in subtype B infection (P = 0.02) and V2-glycan bnAbs in non-subtype B infection (P = 1 × 10^-5), implying that envelope features that differ between viral subtypes steer which antibody class develops; this subtype–specificity association was analysed by exact logistic regression in a multivariable setting controlling for ethnicity, and the reciprocal ethnicity analysis controlled for subtype. Fingerprint-based assignment did not yield a dominant-specificity prediction for every top neutralizing plasma, and no validated high-resolution deconvolution method for V3-glycan and MPER plasma specificities has since been established. The paper concluded that key host, disease and viral determinants, including subtype-specific envelope features that determine bnAb specificity, remained to be unraveled and harnessed for vaccine design.

Problem Statement

Identify the mechanistic determinants that govern whether — and which class of — broadly neutralizing antibodies (bnAbs) develop during HIV-1 infection, as posed by the 2016 Swiss cohort survey (Rusert et al., Nature Medicine 22:1260–1267) and still open: the key host, disease and viral determinants of bnAb induction and of bnAb-class specificity, including the subtype-specific envelope features that determine bnAb specificity, which the survey states remain to be unraveled and harnessed for bnAb-based vaccine design. The specific determinants that the survey's own findings leave unexplained are: (1) the mechanistic basis of the observed higher bnAb induction rates in Black compared with white participants — an association that persisted in multivariable models including all measured demographic, viral and disease parameters — where candidate explanations include, illustratively, host-genetic differences, epidemiological or socioeconomic circumstances at the time of acquisition, coinfection patterns and other environmental influences; (2) the structural and molecular determinants in native HIV-1 envelope trimers that bias bnAb specificity by viral subtype — explaining, at the level of defined trimer features, why subtype B infection preferentially yields CD4-binding-site bnAbs while non-subtype B infection preferentially yields V2-glycan bnAbs, an association the survey tested by exact logistic regression in a multivariable setting controlling for ethnicity (glycan presentation, V1V2/V3 conformations and interprotomer interactions are illustrative candidate features); and (3) why the three antigen-exposure parameters — viral load, length of untreated infection and viral sequence diversity — independently drive bnAb evolution, and what these natural-infection drivers imply for reproducing bnAb induction through vaccination rather than chronic infection. These are the unresolved determinants arising from the survey's findings, not conditions that a single answer must satisfy simultaneously; progress on any of them addresses the same open question.

References

  1. Rusert P, Kouyos RD, Kadelka C, Ebner H, Schanz M, Huber M, Braun DL, Hozé N, Scherrer A, Magnus C, Weber J, Uhr T, Cippa V, Thorball CW, Kuster H, Cavassini M, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Rauch A, Yerly S, Aubert V, Klimkait T, Böni J, Fellay J, Regoes RR, Günthard HF, Trkola A, Swiss HIV Cohort Study (2016) Determinants of HIV-1 broadly neutralizing antibody induction. Nature Medicine 22:1260–1267. doi:10.1038/nm.4187, https://doi.org/10.1038/nm.4187
  2. Schommers P, et al. (2023) Dynamics and durability of HIV-1 neutralization are determined by viral replication. Nature Medicine 29:2763–2774. doi:10.1038/s41591-023-02582-3, https://doi.org/10.1038/s41591-023-02582-3
  3. Lewitus E, et al. (2022) HIV-1 infections with multiple founders associate with the development of neutralization breadth. PLOS Pathogens 18:e1010369. doi:10.1371/journal.ppat.1010369, https://doi.org/10.1371/journal.ppat.1010369
  4. Leggat DJ, Cohen KW, Willis JR, Fulp WJ, deCamp AC, Kalyuzhniy A, et al. (2022) Vaccination induces HIV broadly neutralizing antibody precursors in humans. Science 378:eadd6502. doi:10.1126/science.add6502, https://doi.org/10.1126/science.add6502
  5. Haynes BF, Wiehe K, Borrow P, Saunders KO, Korber B, Wagh K, et al. (2023) Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nature Reviews Immunology 23:142–158. doi:10.1038/s41577-022-00753-w, https://doi.org/10.1038/s41577-022-00753-w
  6. Arandhara M, Kumar Y, Dixit NM, Maiti PK (2025) Clade-Specific Influences of Glycans on the Interactions between HIV-1 Envelope and Broadly Neutralizing Antibodies. Journal of Chemical Information and Modeling 65:13296–13314. doi:10.1021/acs.jcim.5c01051, https://doi.org/10.1021/acs.jcim.5c01051
  7. Habib R, Roark RS, Li H, Connell AJ, et al. (2026) Env-antibody coevolution identifies B cell priming as the principal bottleneck to HIV V2 apex broadly neutralizing antibody development. Science Immunology 11:eadz3933. doi:10.1126/sciimmunol.adz3933, https://doi.org/10.1126/sciimmunol.adz3933, https://pmc.ncbi.nlm.nih.gov/articles/PMC13015429/
  8. Marchitto L, Wagh K, Roark RS, Coleon S, et al. (2026) Enhanced B cell priming induces broadly neutralizing HIV-1 apex antibodies. Nature 656:712–722. doi:10.1038/s41586-026-10838-4, https://doi.org/10.1038/s41586-026-10838-4
  9. Kowarsky M, et al. (2026) Cell-free RNA reveals host and microbial correlates of broadly neutralizing antibody development against HIV. PLOS Pathogens 22:e1014066. doi:10.1371/journal.ppat.1014066, https://doi.org/10.1371/journal.ppat.1014066
  10. Pasin C, Schmidt D, Schanz M, Elie B, Friedrich N, Abela IA, et al. (2024) The XbnAb Cohort: 305 people with broadly neutralizing antibody activity to HIV-1. bioRxiv preprint. doi:10.1101/2024.09.13.612733, https://doi.org/10.1101/2024.09.13.612733
  11. Doria-Rose NA, Klein RM, Daniels MG, O'Dell S, Nason M, et al. (2010) Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. Journal of Virology 84:1631–1636. doi:10.1128/jvi.01482-09, https://doi.org/10.1128/JVI.01482-09